Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Oncologists greet Lumakras: the world’s first KRAS inhibitor

A Publisher Correction to this article was published on 12 October 2021

This article has been updated

The milestone approval for Amgen’s drug Lumakras will galvanize targeted therapy efforts against Ras oncoproteins and provides a powerful new last line of defense for patients with lung cancer.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Change history

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Oncologists greet Lumakras: the world’s first KRAS inhibitor. Nat Biotechnol 39, 1032–1034 (2021). https://doi.org/10.1038/s41587-021-01053-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-01053-9

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing